Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
Immutep Limited announces a focused clinical development strategy for its immunotherapy eftilagimod alfa (efti), concentrating on head and neck squamous cell carcinoma with negative PD-L1 expression and neoadjuvant soft tissue sarcoma. Following unexpected results in the TACTI-004 trial linked to manufacturing scale differences, the company is cond…